{"title": "Publications 2021", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2022-08-18", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Publications 2021\nHoffmeister L, Huebner J, Keinki C, Muenstedt K. Education of non-medical practitioners in Germany-an analysis of course subjects of specialized schools. Wien Med Wochenschr. 2021 Dec 13. English. doi: 10.1007/s10354-021-00896-w. Epub ahead of print. PMID:\n[34902098](https://pubmed.ncbi.nlm.nih.gov/34902098/)\nRetzlaff D, D\u00f6rfler J, Kutschan S, Freuding M, B\u00fcntzel J, H\u00fcbner J (2021) The Vitamin E Isoform \u03b1-Tocopherol is Not Effective as a Complementary Treatment in Cancer Treatment: A Systematic Review, Nutrition and Cancer, DOI:\n[10.1080/01635581.2021.2014905](https://doi.org/10.1080/01635581.2021.2014905)\nHochhaus A, Ernst T: TKI discontinuation in CML: how do we make more patients eli gi ble ? How do we increase the chances of a suc cessful treatment - free remission? Hematology 2021, ASH Education Program, 106-112\nFleischmann M, Fischer M, Schnetzke U, Fortner C, Kirkpatrick J, Heidel FH, Hochhaus A, Scholl S. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance. Cells. 2021 Nov 3;10(11):2992. doi: 10.3390/cells10112992. PMID:\n[34831215](https://pubmed.ncbi.nlm.nih.gov/34831215/)\nJosfeld L, Kr\u00fcger L, B\u00fcntzel J, Zomorodbakhsch B, \u00b7 H\u00fcbner J: Self-efficacy in relation to the use of complementary and alternative medicine, lifestyle choices and cancer aetiology. J Cancer Res Clin Oncol (2021).\n[https://doi.org/10.1007/s00432-021-03857-3](https://link.springer.com/article/10.1007/s00432-021-03857-3)\nMiddeke JM, Metzeler KH, R\u00f6llig C, Kramer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Kraemer A, Hochhaus A, Br\u00fcmmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, G\u00f6rlich D, Sauerland CM, Schaefer-Eckart K, Schliemann C, Krause SW, H\u00e4nel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Woermann B, Sockel K, von Bonin M, Herold T, M\u00fcller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornh\u00e4user M, St\u00f6lzel F, Thiede C. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: Results from a large multicenter study. Blood Adv. 2021 Nov 18:bloodadvances.2021004934. doi: 10.1182/bloodadvances.2021004934. Epub ahead of print. PMID:\n[ 34794176](https://pubmed.ncbi.nlm.nih.gov/34794176/)\nWalter RB, Hochhaus A, Gale RP: Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946\u2013October 8, 2021). Leukemia (2021).\n[https://doi.org/10.1038/s41375-021-01467-z](https://www.nature.com/articles/s41375-021-01467-z#citeas)\nFleischmann M, Schnetzke U, Hochhaus A, Scholl S. Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers (Basel). 2021 Nov 16;13(22):5722. doi: 10.3390/cancers13225722. PMID:\n[34830877](https://pubmed.ncbi.nlm.nih.gov/34830877/)\nVogel J, Zomorodbakhsch B, Thomas Stauch T, Josfeld L, H\u00fcbner J: The role of the general practitioner in cancer care in general and with respect to complementary and alternative medicine for patients with cancer. European Journal of Cancer Care, Received: 26 May 2021 Revised: 10 August 2021 Accepted: 4 October 2021,\n[DOI: 10.1111/ecc.13533](https://onlinelibrary.wiley.com/doi/full/10.1111/ecc.13533)\nO'Hagan Henderson S, Frietsch JJ, Hilgendorf I, Hochhaus A, K\u00f6hne CH, Casper J. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. J Cancer Res Clin Oncol. 2021 Oct 21. doi: 10.1007/s00432-021-03836-8. Epub ahead of print. PMID:\n[34674031](https://pubmed.ncbi.nlm.nih.gov/34674031/)\nSchnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, D\u00f6hner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, Dolnik A, Assi SA, Nafria M, Jiang L, Dai YT, Chen Z, Chen SJ, Kellaway SG, Ptasinska A, Ng ES, Stanley EG, Elefanty AG, Buschbeck M, Bierhoff H, Brodt S, Matziolis G, Fischer KD, Hochhaus A, Chen CW, Heidenreich O, Mann M, Lane SW, Bullinger L, Ori A, Eyss BV, Bonifer C, Heidel F. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood. 2021 Oct 25:blood.2021012778. doi: 10.1182/blood.2021012778. Epub ahead of print. PMID:\n[34695195](https://pubmed.ncbi.nlm.nih.gov/34695195/)\nH\u00fcbner, J., Stoll, C. & Keinki, C. Immunstimulanzien aus der Naturheilkunde und ihr Einsatz bei Neoplasien. Onkologe 27, 1125\u20131130 (2021).\n[https://doi.org/10.1007/s00761-021-01040-4](https://link.springer.com/article/10.1007%2Fs00761-021-01040-4)\nO'Hagan Henderson S, Frietsch JJ, Hilgendorf I, Hochhaus A, K\u00f6hne CH, Casper J. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. J Cancer Res Clin Oncol. 2021 Oct 21. doi: 10.1007/s00432-021-03836-8. Epub ahead of print. PMID:\n[34674031](https://pubmed.ncbi.nlm.nih.gov/34674031/)\nH\u00fcbner, J., Stoll, C. & Keinki, C. Immunstimulanzien aus der Naturheilkunde und ihr Einsatz bei Neoplasien. Onkologe (2021).\n[https://doi.org/10.1007/s00761-021-01040-4](https://link.springer.com/article/10.1007%2Fs00761-021-01040-4)\nH\u00fcbner J, Beckmann M , Follmann M, Nothacker M, Prott FJ, W\u00f6rmann B: Komplement\u00e4rmedizin in der Behandlung von onkologisch erkrankten Patienten; Dtsch Arztebl Int 2021; 118: 654-9;\n[DOI: 10.3238/arztebl.m2021.0277](https://www.aerzteblatt.de/archiv/221314/Komplementaermedizin-in-der-Behandlung-von-onkologisch-erkrankten-Patienten)\nGale RP, Hochhaus A, Cross NCP, Harrison CJ: HGNC nomenclature for fusion genes. Leukemia (2021).\n[https://doi.org/10.1038/s41375-021-01437-5](https://www.nature.com/articles/s41375-021-01437-5)\nM\u00fchleck, R., Scholl, S., Hilgendorf, I. et al. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. J Cancer Res Clin Oncol 148, 2539\u20132548 (2022).\n[https://doi.org/10.1007/s00432-021-03821-1](https://link.springer.com/article/10.1007/s00432-021-03821-1)\nReuken PA, R\u00fcthrich MM, Hochhaus A, Hammersen J, Bauer M, La Ros\u00e9e P, La Ros\u00e9e F, Stallmach A: The impact of specific cytokine directed treatment on severe COVID-19. Leukemia. 2021 Sep 7:1\u20133. doi: 10.1038/s41375-021-01411-1. Epub ahead of print. PMID:\n[34493799](https://pubmed.ncbi.nlm.nih.gov/34493799/); PMCID: PMC8422045.\nD\u00f6hner H, Malcovati L, Ossenkoppele GJ, Hochhaus A, Maria Vannucchi A, Bullinger L, Cervantes F, Craddock C, de Witte T, D\u00f6hner K, Dombret H, Fenaux P, Geissler J, Germing U, Guilhot F, Harrison C, Hellstr\u00f6m-Lindberg E, Passamonti F, Sierra J, Skoda R, Wierzbowska A. The EHA Research Roadmap: Malignant Myeloid Diseases. Hemasphere. 2021 Aug 26;5(9):e635. doi: 10.1097/HS9.0000000000000635. PMID: 34476345; PMCID:\n[PMC8389885](https://pubmed.ncbi.nlm.nih.gov/34476345/)\nHeinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, H\u00e4hling D, Hegenbart U, Peter N, Schulze A, Florsch\u00fctz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Sp\u00e4th C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021 Sep;100(9):2387-2398. doi: 10.1007/s00277-021-04565-1. Epub 2021 Jul 7. PMID:\n[34232360](https://pubmed.ncbi.nlm.nih.gov/34232360/)\nO'Hagan Henderson S, Glaser A, Frietsch JJ, Hochhaus A, Hilgendorf I. The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. Ann Hematol. 2021 Sep 1. doi: 10.1007/s00277-021-04655-0. Epub ahead of print. PMID:\n[34471943](https://pubmed.ncbi.nlm.nih.gov/34471943/)\nStasik S, Eckardt JN, Kramer M, R\u00f6llig C, Kr\u00e4mer A, Scholl S, Hochhaus A, Crysandt M, Br\u00fcmmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Sch\u00e4fer-Eckart K, Schliemann C, Krause S, Herbst R, H\u00e4nel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, R\u00e1cil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, M\u00fcller-Tidow C, Ehninger G, Bornh\u00e4user M, Schetelig J, Middeke JM, Thiede C; Study Alliance Leukemia (SAL). Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv. 2021 Sep 14;5(17):3279-3289. doi: 10.1182/bloodadvances.2021004631. PMID:\n[34459887](https://pubmed.ncbi.nlm.nih.gov/34459887/)\nH\u00fcbner J, M\u00fcnstedt K, Micke O, Prott FJ,Schmidt T, B\u00fcntzel J: Zentrale Empfehlungen und Statements der S3-Leitlinie zur komplement\u00e4ren Medizin f\u00fcr Patient*innen mit onkologischen Erkrankungen \u2013 Teil 2. Onkologe 27, 917\u2013921 (2021). https://doi.\n[org/10.1007/s00761-021-00990-z](https://link.springer.com/article/10.1007%2Fs00761-021-00990-z)\nR\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garc\u00eda-Guti\u00e9rrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, B\u00e9doucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. PMID:\n[34407542](https://pubmed.ncbi.nlm.nih.gov/34407542/)\nCortes J, Apperley JF, Lomaia E, Moiraghi B, Undurraga MS, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur C, Maness LJ, Talpaz M, Mauro MJ, Hall T, Lu V, Srivastava S, Deininger MW. Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. Blood. 2021 Aug 18:blood.2021012082. doi: 10.1182/blood.2021012082. Epub ahead of print. PMID:\n[34407543](https://pubmed.ncbi.nlm.nih.gov/34407543/)\nHoppe C, Freuding M, B\u00fcntzel J, M\u00fcnstedt K, H\u00fcbner J: Clinical efficacy and safety of oral and intravenous vitamin C use in patients with malignant diseases. J Cancer Res Clin Oncol (2021).\n[https://doi.org/10.1007/s00432-021-03759-4](https://link.springer.com/article/10.1007%2Fs00432-021-03759-4#citeas)\nSchnetzke U: Aggressives B-Zell-Lymphom: Registerstudien best\u00e4tigen die Wirksamkeit von CAR-T-Zell-Therapien. Kompass Onkol 2021. doi:\n[10.1159/000518702](https://www.karger.com/Article/Abstract/518702)\nTaube F, Georgi JA, Kramer M, Stasik S, Middeke JM, R\u00f6llig C, Krug U, Kr\u00e4mer A, Scholl S, Hochhaus A, Br\u00fcmmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Sch\u00e4fer-Eckart K, Schliemann C, Krause SW, H\u00e4nel M, Noppeney R, Kaiser U, Baldus C, Kaufmann M, Herold S, St\u00f6lzel F, Sockel K, von Bonin M, M\u00fcller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornh\u00e4user M, Schetelig J, Thiede C. CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. Blood. 2021 Jul 28:blood.2020009680. doi: 10.1182/blood.2020009680. Epub ahead of print. PMID:\n[34320176](https://pubmed.ncbi.nlm.nih.gov/34320176/)\nRuhe J, Schnetzke U, Kentouche K, Prims F, Baier M, Herfurth K, Schlosser M, Busch M, Hochhaus A, Wolf G. Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine. Ann Hematol. 2021 Jul 26. doi: 10.1007/s00277-021-04584-y. Epub ahead of print. PMID:\n[34309715](https://pubmed.ncbi.nlm.nih.gov/34309715/)\nFleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J, Glaser A, Hilgendorf I, Hochhaus A, Scholl S. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. J Cancer Res Clin Oncol. 2021 Jul 23. doi: 10.1007/s00432-021-03733-0. Epub ahead of print. PMID:\n[34297206](https://pubmed.ncbi.nlm.nih.gov/34297206/)\nH\u00fcbner J, M\u00fcnstedt K, Micke O, Prott FJ, Schmidt T, B\u00fcntzel J: Zentrale Empfehlungen und Statements der S3-Leitlinie zur komplement\u00e4ren Medizin f\u00fcr Patient*innen mit onkologischen Erkrankungen \u2013 Teil 1. Onkologe 27, 795\u2013801 (2021).\n[https://doi.org/10.1007/s00761-021-00989-6](https://link.springer.com/article/10.1007%2Fs00761-021-00989-6)\nGericke M., Geitel, J\u00f6rke C, Clement JH, Heinze T: Reactive Nanoparticles Derived from Polysaccharide Phenyl Carbonates. Molecules 2021, 26, 4026.\n[https://doi.org/10.3390/molecules26134026](https://www.mdpi.com/1420-3049/26/13/4026)\nH\u00fcbner J, M\u00fccke R, Micke O, Keinki C: Komplement\u00e4rmedizin in der Uroonkologie. Urologe 60, 953\u2013962 (2021). https://doi.org/\n[10.1007/s00120-021-01584-8](https://link.springer.com/article/10.1007/s00120-021-01584-8#citeas)\nGremmler L, Kutschan S, D\u00f6rfler J, B\u00fcntzel J, B\u00fcntzel J, H\u00fcbner J. Proteolytic Enzyme Therapy in Complementary Oncology: A Systematic Review. Anticancer Res. 2021 Jul;41(7):3213-3232. doi: 10.21873/anticanres.15108. Epub 2021 Jul 5. PMID:\n[34230116](https://pubmed.ncbi.nlm.nih.gov/34230116/)\nKr\u00fcger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Niederwieser D, D\u00f6lken G. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014 Sep;93(9):1587-97. doi: 10.1007/s00277-014-2087-z. Epub 2014 Apr 30. PMID:\n[24782119](https://pubmed.ncbi.nlm.nih.gov/24782119/)\nWolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Huebner J. Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. J Cancer Res Clin Oncol. 2021 Jul 6. doi: 10.1007/s00432-021-03675-7. Epub ahead of print. PMID:\n[34228225](https://pubmed.ncbi.nlm.nih.gov/34228225/)\nvon Lilienfeld-Toal M, Rieger C, Giesen N. et al. Impfung gegen SARS-CoV-2 bei Krebspatienten. Onkologe 27, 691\u2013696 (2021).\n[https://doi.org/10.1007/s00761-021-00972-1](https://link.springer.com/article/10.1007/s00761-021-00972-1)\nMickoleit F, J\u00f6rke C, Geimer S, Maier D, M\u00fcller JP, Demut J, Gr\u00e4fe C, Sch\u00fcler D, Clement JH. 2021. Biocompatibility, uptake and subcellular localization of bacterial magnetosomes in mammalian cells. Nanoscale Advances:\n[https://doi.org/10.1039/D0NA01086C](https://doi.org/10.1039/D0NA01086C)\nMiddeke JM, Teipel R, R\u00f6llig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Br\u00fcmmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, St\u00f6lzel F, Platzbecker U, Ehninger G, Bornh\u00e4user M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Leuk Lymphoma. 2021 Jun;62(6):1432-1440. doi: 10.1080/10428194.2020.1864354. Epub 2021 Jan 5. PMID:\n[33399480](https://pubmed.ncbi.nlm.nih.gov/33399480/)\nPetr Vitek P, Koscielny S, B\u00fcssing A, H\u00fcbner J, B\u00fcntzel J. Religiosit\u00e4t und Spiritualit\u00e4t als Ressourcen in der Betreuung von Patienten mit Kopf-Hals-Tumoren; Laryngorhinootologie 2021; DOI:\n[10.1055/a-1516-4589](https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1516-4589)\nB\u00fcssing A, Recchia DR, H\u00fcbner J, Walter S, B\u00fcntzel J, B\u00fcntzel J. Tumor patients' fears and worries and perceived changes of specific attitudes, perceptions and behaviors due to the COVID-19 pandemic are still relevant. J Cancer Res Clin Oncol. 2021 Jun;147(6):1673-1683. doi: 10.1007/s00432-021-03573-y. Epub 2021 Mar 6. PMID:\n[33675401](https://pubmed.ncbi.nlm.nih.gov/33675401/); PMCID: PMC7936591\nWelter S, Keinki C, Ahmadi E, Huebner J. Lay Etiology, Self-Efficacy and Patient Activation Among Cancer Patients. Cancer Invest. 2021 Mar;39(3):219-228. doi: 10.1080/07357907.2021.1878528. Epub 2021 Feb 2. PMID:\n[33475001](https://pubmed.ncbi.nlm.nih.gov/33475001/)\nBaier L, H\u00fcbner J, Kerschbaum E, Erickson N. Krebsdi\u00e4ten: patientenzentrierte Kommunikationsstrategien; Onkologe 2021; 27:148\u2013153\nM\u00e4nnle H, Momm F, H\u00fcbner J, M\u00fcnstedt K. Do breast cancer patients adapt CAM methods according to the therapeutic situation? Complement Ther Clin Pract. 2021 May;43:101305. doi: 10.1016/j.ctcp.2021.101305. Epub 2021 Jan 23. PMID:\n[33516058](https://pubmed.ncbi.nlm.nih.gov/33516058/)\nGiesen N, Sprute R, R\u00fcthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, W\u00f6rmann B, Cornely OA, K\u00f6hler P, Schalk E, von Lilienfeld-Toal M; COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021 Apr;147:154-160. doi: 10.1016/j.ejca.2021.01.033. Epub 2021 Feb 10. PMID:\n[33676266](https://pubmed.ncbi.nlm.nih.gov/33676266/); PMCID: PMC7874914\nSchmoll HJ; Lindner LH, Reichardt P, Hei\u00dfner K, Kopp HG, Kessler T, Mayer-Steinacker R, R\u00fcssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, MD12; Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A: Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(2):255-262. doi:10.1001/jamaoncol.2020.6564\nEyre TA, Caillard S, Finel H, Boumendil A, Kothari J, Zimmermann H, Trappe RU, De Wilde V, Tholouli E, Kanfer E, Broom A, Damaj G, Bargetzi M, Koz\u00e1k T, Hilgendorf I, Crawley C, Kerre T, Trn\u011bn\u00fd M, Bachy E, Robinson S, Montoto S. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2021 Apr 16. doi: 10.1038/s41409-021-01270-5. Epub ahead of print. PMID:\n[33864020](https://pubmed.ncbi.nlm.nih.gov/33864020/)\nSchrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, Griesshammer M, Wille K; German Study Group MPN, GSG-MPN. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin Oncol. 2021 May;147(5):1481-1491. doi: 10.1007/s00432-020-03430-4. Epub 2020 Nov 2. PMID:\n[33140210](https://pubmed.ncbi.nlm.nih.gov/33140210/)\nGraf La Ros\u00e9e, H.-C. Bremer, F. La Ros\u00e9e, P. Mohm, A. Hochhaus, I. Gehrke, B. Kumle, A. Benzing & S. Russo: Interdisziplin\u00e4res COVID-Board bei SARS-CoV-2-getriggerter hyperferritin\u00e4mischer Inflammation. MedKlin IntensivmedNotfmed2021, 116:138\u2013145,\n[https://doi.org/10.1007/s00063-020-00750-8](https://link.springer.com/article/10.1007/s00063-020-00750-8)\nBrioli A, Manz K, Pfirrmann M, H\u00e4nel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, M\u00fcgge LO. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2. PMID:\n[31788741](https://pubmed.ncbi.nlm.nih.gov/31788741/)\nB\u00fcntzel J, Walter S, Hellmund H, Klein M, H\u00fcbner J, Vitek P, B\u00fcntzel J, Koscielny S, Sesterhenn AM, B\u00fcssing A. Auswirkungen der COVID-19-Pandemie auf die Versorgung von HNO-Tumoren \u2013 die Patientenperspektive [Oncology Services for Patients with Head Neck Cancer during Corona-Times - Patients' Perspective]. Laryngorhinootologie. 2021 Feb;100(2):104-110. German. doi: 10.1055/a-1327-4234. Epub 2020 Dec 14. PMID:\n[33316831](https://pubmed.ncbi.nlm.nih.gov/33316831/)\nCiarlo G, Ahmadi E, Welter S, H\u00fcbner J. Factors influencing the usage of complementary and alternative medicine by patients with cancer. Complement Ther Clin Pract. 2021 Apr 15;44:101389. doi: 10.1016/j.ctcp.2021.101389. Epub ahead of print. PMID:\n[33932731](https://pubmed.ncbi.nlm.nih.gov/33932731/)\nChristiansen N, Walter S, Zomorodbakhsch B, Sartakhti EA, H\u00fcbner J. Assessment of Self-Efficacy as a Way to Help Identify Cancer Patients Who Might Benefit from Self-Help Group Attendance? Cancer Invest. 2021 Feb;39(2):133-143. doi: 10.1080/07357907.2020.1867996. Epub 2021 Jan 6. PMID:\n[33356618](https://pubmed.ncbi.nlm.nih.gov/33356618/)\nJosfeld L, Keinki C, Pammer C, Zomorodbakhsch B, H\u00fcbner J. Cancer patients' perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol. 2021 Jun;147(6):1725-1732. doi: 10.1007/s00432-021-03579-6. Epub 2021 Mar 7. PMID:\n[33682014](https://pubmed.ncbi.nlm.nih.gov/33682014/); PMCID: PMC8076112\nMorkramer L, Geitner M, Boeger D, Buentzel J, \u00b7 Kaftan H, \u00b7 Mueller AH,\u00b7Ernst T, \u00b7 Guntinas\u2011Lichius O: Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany. J Cancer Res Clin Oncol (2021). https://doi.org/\n[10.1007/s00432-021-03535-4](https://link.springer.com/article/10.1007/s00432-021-03535-4)\nB\u00fcntzel J, Micke O, Klein M, B\u00fcntzel J, Walter S, Keinki C, Huebner J. Take care or \"German Angst\"? Lessons from cancer care during COVID-19 pandemic in spring 2020. J Cancer Res Clin Oncol (2021) 147:2093\u20132105. doi: 10.1007/s00432-020-03492-4. Epub ahead of print. PMID:\n[33387036](https://pubmed.ncbi.nlm.nih.gov/33387036/); PMCID: PMC7776312\nR\u00f6mer M, D\u00f6rfler J, Huebner J. The use of ketogenic diets in cancer patients: a systematic review. Clin Exp Med. 2021 Apr 3. doi: 10.1007/s10238-021-00710-2. Epub ahead of print. PMID:\n[33813635](https://pubmed.ncbi.nlm.nih.gov/33813635/)\nHoppe C, Kutschan S, D\u00f6rfler J, B\u00fcntzel J, B\u00fcntzel J, Huebner J. Zinc as a complementary treatment for cancer patients: a systematic review. Clin Exp Med. 2021 May;21(2):297-313. doi: 10.1007/s10238-020-00677-6. Epub 2021 Jan 26. PMID:\n[33496846](https://pubmed.ncbi.nlm.nih.gov/33496846/); PMCID: PMC8053661\nKeinki C, Momberg A, Clau\u00df K, Bozkurt G, Hertel E, Freuding M, Josfeld L, Huebner J. Effect of question prompt lists for cancer patients on communication and mental health outcomes-A systematic review. Patient Educ Couns. 2021 Jan 15:S0738-3991(21)00039-2. doi: 10.1016/j.pec.2021.01.012. Epub ahead of print. PMID:\n[33593643](https://pubmed.ncbi.nlm.nih.gov/33593643/)\nWiese F, Kutschan S, Doerfler J, Mathies V, Buentzel J, Buentzel J, Huebner J. Green tea and green tea extract in oncological treatment: A systematic review. Int J Vitam Nutr Res. 2021 Feb 17:1-13. doi: 10.1024/0300-9831/a000698. Epub ahead of print. PMID:\n[33593083](https://pubmed.ncbi.nlm.nih.gov/33593083/)\nThieser S, D\u00f6rfler J, Rudolph I, Wozniak T, Schmidt T, H\u00fcbner J. Influence of ballroom dancing on fatigue, body image, self-efficacy, and endurance of cancer patients and their partners. Med Oncol. 2021 Jan 28;38(2):15. doi: 10.1007/s12032-021-01459-0. PMID:\n[33507443](https://pubmed.ncbi.nlm.nih.gov/33507443/); PMCID: PMC7843482\nSonneborn-Papakostopoulos M, Dubois C, Mathies V, He\u00df M, Erickson N, Ernst T, Huebner J. Quality of life, symptoms and dietary habits in oncology outpatients with malnutrition: A cross-sectional study. Med Oncol. 2021 Feb 4;38(2):20. doi: 10.1007/s12032-021-01460-7. PMID:\n[33543336](https://pubmed.ncbi.nlm.nih.gov/33543336/); PMCID: PMC7862192\nEckardt JN, Stasik S, Kramer M, R\u00f6llig C, Kr\u00e4mer A, Scholl S, Hochhaus A, Crysandt M, Br\u00fcmmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Sch\u00e4fer-Eckart K, Schliemann C, Krause SW, Herbst R, H\u00e4nel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, R\u00e1cil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, M\u00fcller-Tidow C, Ehninger G, St\u00f6lzel F, Kroschinsky F, Schetelig J, Bornh\u00e4user M, Thiede C, Middeke JM. Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers (Basel). 2021 Apr 26;13(9):2095. doi: 10.3390/cancers13092095. PMID:\n[33926021](https://pubmed.ncbi.nlm.nih.gov/33926021/)\nWolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, H\u00fcbner J. Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements. J Cancer Res Clin Oncol. 2021 Apr 17. doi: 10.1007/s00432-021-03625-3. Epub ahead of print. PMID:\n[33864520](https://pubmed.ncbi.nlm.nih.gov/33864520/)\nDufter SA, H\u00fcbner J, Ahmadi E, Zomorodbakhsch B. Traits of cancer patients and CAM usage. J Cancer Res Clin Oncol. 2021 Dec;147(12):3685-3692. doi: 10.1007/s00432-021-03605-7. Epub 2021 Apr 2. PMID:\n[33811274](https://pubmed.ncbi.nlm.nih.gov/33811274/)\nErnst P, Heidel FH. Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. Cancers (Basel). 2021 Feb 4;13(4):612. doi: 10.3390/cancers13040612. PMID:\n[33557090](https://pubmed.ncbi.nlm.nih.gov/33557090/); PMCID: PMC7913823\nPalandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. PMID:\n[33414394](https://pubmed.ncbi.nlm.nih.gov/33414394/); PMCID: PMC7791065\nPolverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17192. Epub ahead of print. PMID:\n[33222197](https://pubmed.ncbi.nlm.nih.gov/33222197/)\nBenevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843. Epub ahead of print. PMID:\n[33590502](https://pubmed.ncbi.nlm.nih.gov/33590502/)\nHeidel FH, Platzbecker U. The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies? Hemasphere. 2021 Feb 10;5(3):e537. doi: 10.1097/HS9.0000000000000537. PMID:\n[33604515](https://pubmed.ncbi.nlm.nih.gov/33604515/); PMCID: PMC7886402\nPalandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer. 2021 Apr 1. doi: 10.1002/cncr.33541. Epub ahead of print. PMID:\n[33794557](https://pubmed.ncbi.nlm.nih.gov/33794557/)\nLoncarevic IF, Toepfer S, Hubold S, Klingner S, Kanitz L, Ellinger T, Steinmetzer K, Ernst T, Hochhaus A, Ermantraut E. Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads. PLoS One. 2021 Mar 18;16(3):e0242529. doi: 10.1371/journal.pone.0242529. PMID:\n[33735175](https://pubmed.ncbi.nlm.nih.gov/33735175/)\nFrietsch JJ, Hunstig F, Wittke C, Junghanss C, Franiel T, Scholl S, Hochhaus A, Hilgendorf I. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant. 2021 Jan;56(1):101-109. doi: 10.1038/s41409-020-0984-4. Epub 2020 Jun 30. PMID:\n[32606455](https://pubmed.ncbi.nlm.nih.gov/32606455/); PMCID: PMC7796857\nHinze A, Rinke J, Hochhaus A, Ernst T. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation. Ann Hematol. 2021 Feb;100(2):581-584. doi: 10.1007/s00277-020-04152-w. Epub 2020 Jun 23. PMID:\n[32577845](https://pubmed.ncbi.nlm.nih.gov/32577845/); PMCID: PMC7817602\nPulewka K, Strauss B, Hochhaus A, Hilgendorf I. Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021 Apr;147(4):1239-1246. doi: 10.1007/s00432-020-03419-z. Epub 2020 Oct 14. PMID:\n[33052515](https://pubmed.ncbi.nlm.nih.gov/33052515/)\nRadich JP, Hochhaus A, Masszi T. et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia (2021).\n[https://doi.org/10.1038/s41375-021-01205-5](https://www.nature.com/articles/s41375-021-01205-5#citeas)\nSch\u00e4fer V, White HE, Gerrard G, M\u00f6bius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. J Cancer Res Clin Oncol. 2021 Mar 7. doi: 10.1007/s00432-021-03569-8. Epub ahead of print. PMID:\n[33677711](https://pubmed.ncbi.nlm.nih.gov/33677711/)\nRichter F, Mapfumo P, Martin L, Solomun JI, Hausig F, Frietsch JJ, Ernst T, Hoeppener S, Brendel JC & Traeger A: Improved gene delivery to K-562 leukemia cells by lipoic acid modified block copolymer micelles. J Nanobiotechnol 19, 70 (2021).\n[https://doi.org/10.1186/s12951-021-00801-y](https://doi.org/10.1186/s12951-021-00801-y)\nWagner-Drouet E, Teschner D, Wolschke C, Sch\u00e4fer-Eckart K, G\u00e4rtner J, Mielke S, Schreder M, Kobbe G, Hilgendorf I, Klein S et al. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics 2021, 11, 312.\n[https://doi.org/10.3390/diagnostics11020312](https://www.mdpi.com/2075-4418/11/2/312)\nSchrenk KG: Systemtherapie von Sarkomen.\n[\u00c4rzteblatt TH\u00dcRINGEN \u00b7 2/2021, 13-15](https://www.aerzteblatt-thueringen.de/pdf/thu2102_013.pdf)\nVogt M, Langenberg J, Sch\u00fcle S, Aschenbach R, Schrenk KG, Hofmann GO: Die strukturierte Tumornachsorge bei Sarkomen \u2013 zehn Jahre nach der Therapie.\n[\u00c4rzteblatt TH\u00dcRINGEN \u00b7 2/2021, 16-19](https://www.aerzteblatt-thueringen.de/pdf/thu2102_016.pdf)\nHenn S, H\u00fcbner J, Sch\u00e4fer S, Uhde A, Zorn A: Erfassung regionaler Unterschiede in der Krebspr\u00e4vention in Th\u00fcringen: der Krebspr\u00e4ventionsinfrastruktur-Index. Forum 2021 \u00b7 36:67\u201368,\n[https://doi.org/10.1007/s12312-020-00877-x](https://doi.org/10.1007/s12312-020-00877-x), Online publiziert: 11. Januar 2021 \u00a9 Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021\nRachow T, Schiffl H, Lang SM. Risk of lung cancer and renin-angiotensin blockade: a concise review. J Cancer Res Clin Oncol. 2021 Jan;147(1):195-204. doi: 10.1007/s00432-020-03445-x. Epub 2020 Nov 24. PMID:\n[33231730](https://pubmed.ncbi.nlm.nih.gov/33231730/); PMCID: PMC7684567\nBrioli A., Hochhaus A. (2021) Immune Checkpoint Blockade. In: Offermanns S., Rosenthal W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham.\n[https://doi.org/10.1007/978-3-030-21573-6_10053-1](https://link.springer.com/referenceworkentry/10.1007/978-3-030-21573-6_10053-1)\nVoigt M, Sinn K, Malouhi A, Gecks T, Zinke J, Hilgendorf I, Scholl S, Hochhaus A, Schnetzke U. HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient. Ann Hematol. 2021 Jan 14. doi: 10.1007/s00277-021-04409-y. Epub ahead of print. PMID:\n[33443593](https://pubmed.ncbi.nlm.nih.gov/33443593/)\nLennart J. Gresing, Patricia Radon, Ralf P. Friedrich, Diana Zahn, Martin Raasch, Alexander S. Mosig, Silvio Dutz, Christoph Alexiou, Frank Wiekhorst, Andreas Hochhaus, Joachim H. Clement: Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner. Journal of Magnetism and Magnetic Materials, Volume 521, Part 2, 2021, 167535, ISSN 0304-8853,\n[https://doi.org/10.1016/j.jmmm.2020.167535](https://doi.org/10.1016/j.jmmm.2020.167535). (http://www.sciencedirect.com/science/article/pii/S0304885320325026)\nSch\u00fcle S, Gampe M, Lindig U, Pelli M, Settmacher U: Gastrointestinale Stromatumore (GIST). \u00c4RZTEBLAT 26 T TH\u00dcRINGEN \u00b7 1/2021, 25-27\nKantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Viviane Dubruille, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia (2021).\n[https://doi.org/10.1038/s41375-020-01111-2](https://doi.org/10.1038/s41375-020-01111-2)\nMiddeke JM, Teipel R, R\u00f6llig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Br\u00fcmmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, St\u00f6lzel F, Platzbecker U, Ehninger G, Bornh\u00e4user M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Leuk Lymphoma. 2021 Jan 5:1-15. doi: 10.1080/10428194.2020.1864354. Epub ahead of print. PMID:\n[33399480](https://pubmed.ncbi.nlm.nih.gov/33399480/).", "language": null, "image": null, "pagetype": null, "links": ["/", "#a_navigation", "#a_content", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications.html", "/Patienten+_+Angeh%C3%B6rige/Im+Notfall.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2021.print", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2021-font-15.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2021-font-14.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2021-font-13.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2021.html", "/kim2/", "/", "/", "/kim2/en/", "/Patienten+_+Angeh%C3%B6rige/Im+Notfall.html", "/kim2/en/KIM+II.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Our+Team.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Our+Services.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Scientific+Focus.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Research+groups.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Clinical+Trials+Coordination.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/The+German+CML+Alliance.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2023.html", "/kim2/en/veranstaltungen.html", "#", "/en/Patients+_+Relatives-p-2.html", "/en/Research.html", "/en/Teaching+and+study.html", "/en/Doctors+_+Referrers-p-12.html", "/en/career.html", "/en/Clinics+_+Institutes-p-16.html", "/en/University+Hospital.html", "#", "/en/Patients+_+Relatives-p-2.html", "/en/Research.html", "/en/Teaching+and+study.html", "/en/Doctors+_+Referrers-p-12.html", "/en/career.html", "/en/Clinics+_+Institutes-p-16.html", "/en/University+Hospital.html", "/kim2/en/KIM+II.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Our+Team.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Our+Services.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Scientific+Focus.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Research+groups.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Clinical+Trials+Coordination.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/The+German+CML+Alliance.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2023.html", "/kim2/en/veranstaltungen.html", "/kim2/en/", "/kim2/en/KIM+II.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications.html", "/kim2/en/KIM+II/Haematology+and+Medical+Oncology/Research/Publications/Publications+2021.html", null, "https://pubmed.ncbi.nlm.nih.gov/34902098/", "https://doi.org/10.1080/01635581.2021.2014905", "https://pubmed.ncbi.nlm.nih.gov/34831215/", "https://link.springer.com/article/10.1007/s00432-021-03857-3", "https://pubmed.ncbi.nlm.nih.gov/34794176/", "https://www.nature.com/articles/s41375-021-01467-z#citeas", "https://pubmed.ncbi.nlm.nih.gov/34830877/", "https://onlinelibrary.wiley.com/doi/full/10.1111/ecc.13533", "https://pubmed.ncbi.nlm.nih.gov/34674031/", "https://pubmed.ncbi.nlm.nih.gov/34695195/", "https://link.springer.com/article/10.1007%2Fs00761-021-01040-4", "https://pubmed.ncbi.nlm.nih.gov/34674031/", "https://link.springer.com/article/10.1007%2Fs00761-021-01040-4", "https://www.aerzteblatt.de/archiv/221314/Komplementaermedizin-in-der-Behandlung-von-onkologisch-erkrankten-Patienten", "https://www.nature.com/articles/s41375-021-01437-5", "https://link.springer.com/article/10.1007/s00432-021-03821-1", "https://pubmed.ncbi.nlm.nih.gov/34493799/", "https://pubmed.ncbi.nlm.nih.gov/34476345/", "https://pubmed.ncbi.nlm.nih.gov/34232360/", "https://pubmed.ncbi.nlm.nih.gov/34471943/", "https://pubmed.ncbi.nlm.nih.gov/34459887/", "https://link.springer.com/article/10.1007%2Fs00761-021-00990-z", "https://pubmed.ncbi.nlm.nih.gov/34407542/", "https://pubmed.ncbi.nlm.nih.gov/34407543/", "https://link.springer.com/article/10.1007%2Fs00432-021-03759-4#citeas", "https://www.karger.com/Article/Abstract/518702", "https://pubmed.ncbi.nlm.nih.gov/34320176/", "https://pubmed.ncbi.nlm.nih.gov/34309715/", "https://pubmed.ncbi.nlm.nih.gov/34297206/", "https://link.springer.com/article/10.1007%2Fs00761-021-00989-6", "https://www.mdpi.com/1420-3049/26/13/4026", "https://link.springer.com/article/10.1007/s00120-021-01584-8#citeas", "https://pubmed.ncbi.nlm.nih.gov/34230116/", "https://pubmed.ncbi.nlm.nih.gov/24782119/", "https://pubmed.ncbi.nlm.nih.gov/34228225/", "https://link.springer.com/article/10.1007/s00761-021-00972-1", "https://doi.org/10.1039/D0NA01086C", "https://pubmed.ncbi.nlm.nih.gov/33399480/", "https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1516-4589", "https://pubmed.ncbi.nlm.nih.gov/33675401/", "https://pubmed.ncbi.nlm.nih.gov/33475001/", "https://pubmed.ncbi.nlm.nih.gov/33516058/", "https://pubmed.ncbi.nlm.nih.gov/33676266/", "https://pubmed.ncbi.nlm.nih.gov/33864020/", "https://pubmed.ncbi.nlm.nih.gov/33140210/", "https://link.springer.com/article/10.1007/s00063-020-00750-8", "https://pubmed.ncbi.nlm.nih.gov/31788741/", "https://pubmed.ncbi.nlm.nih.gov/33316831/", "https://pubmed.ncbi.nlm.nih.gov/33932731/", "https://pubmed.ncbi.nlm.nih.gov/33356618/", "https://pubmed.ncbi.nlm.nih.gov/33682014/", "https://link.springer.com/article/10.1007/s00432-021-03535-4", "https://pubmed.ncbi.nlm.nih.gov/33387036/", "https://pubmed.ncbi.nlm.nih.gov/33813635/", "https://pubmed.ncbi.nlm.nih.gov/33496846/", "https://pubmed.ncbi.nlm.nih.gov/33593643/", "https://pubmed.ncbi.nlm.nih.gov/33593083/", "https://pubmed.ncbi.nlm.nih.gov/33507443/", "https://pubmed.ncbi.nlm.nih.gov/33543336/", "https://pubmed.ncbi.nlm.nih.gov/33926021/", "https://pubmed.ncbi.nlm.nih.gov/33864520/", "https://pubmed.ncbi.nlm.nih.gov/33811274/", "https://pubmed.ncbi.nlm.nih.gov/33557090/", "https://pubmed.ncbi.nlm.nih.gov/33414394/", "https://pubmed.ncbi.nlm.nih.gov/33222197/", "https://pubmed.ncbi.nlm.nih.gov/33590502/", "https://pubmed.ncbi.nlm.nih.gov/33604515/", "https://pubmed.ncbi.nlm.nih.gov/33794557/", "https://pubmed.ncbi.nlm.nih.gov/33735175/", "https://pubmed.ncbi.nlm.nih.gov/32606455/", "https://pubmed.ncbi.nlm.nih.gov/32577845/", "https://pubmed.ncbi.nlm.nih.gov/33052515/", "https://www.nature.com/articles/s41375-021-01205-5#citeas", "https://pubmed.ncbi.nlm.nih.gov/33677711/", "https://doi.org/10.1186/s12951-021-00801-y", "https://www.mdpi.com/2075-4418/11/2/312", "https://www.aerzteblatt-thueringen.de/pdf/thu2102_013.pdf", "https://www.aerzteblatt-thueringen.de/pdf/thu2102_016.pdf", "https://doi.org/10.1007/s12312-020-00877-x", "https://pubmed.ncbi.nlm.nih.gov/33231730/", "https://link.springer.com/referenceworkentry/10.1007/978-3-030-21573-6_10053-1", "https://pubmed.ncbi.nlm.nih.gov/33443593/", "https://doi.org/10.1016/j.jmmm.2020.167535", "https://doi.org/10.1038/s41375-020-01111-2", "https://pubmed.ncbi.nlm.nih.gov/33399480/", "/kim2/en/KIM+II.html", "https://de-de.facebook.com/UniklinikJena/", "https://twitter.com/ukj_jena?lang=de", "https://www.youtube.com/channel/UC9PAD851qLQBqw3PPFFnYIw", "https://de-de.facebook.com/UniklinikJena/", "https://twitter.com/ukj_jena?lang=de", "https://www.youtube.com/channel/UC9PAD851qLQBqw3PPFFnYIw", "https://www.uni-jena.de/", "https://uniklinika.de/"]}